Archives of Virology

, Volume 163, Issue 7, pp 1993–1996 | Cite as

Complete genome sequence of a novel virulent phage ST31 infecting Escherichia coli H21

  • Honghui Liu
  • Yanwen Xiong
  • Xinchun LiuEmail author
  • Jinqing Li
Annotated Sequence Record


More and more virulent phages that are fundamental materials for phage therapy have been isolated, characterized and categorized on GenBank. Phage ST31 infecting Escherichia coli H21 was isolated from wastewater and sequenced using an Illumina Hiseq system. Opening reading frames were identified using PHASTER and predicted using BLASTp analysis. Genomic analyses revealed that this was a virulent phage containing a circular double-stranded DNA and that the complete genome consisted of 39,693 nucleotides with an average GC content of 49.98 %. This study may provide possible alternative materials for phage therapy.



We wish to thank Miss Jingnan Liang of the Institute of Microbiology, Chinese Academy of Sciences for her assistance in TEM sample preparation.


This study was funded by grant National Natural Science Foundation of China (NO. 50978250 and NO. 51378485), and the Resources and Environment Bureau of Chinese Academy of Sciences (NO.Y225018EA2).

Conflict of interest

There are not conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

705_2018_3812_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 16 kb)


  1. 1.
    Franklin LN, Ana RC, Leon DK et al (2015) Revisiting phage therapy: new applications for old resources. Trends Mirobiol 23(4):185–191CrossRefGoogle Scholar
  2. 2.
    Elizabeth K, Daniel DV, Guram G et al (2010) Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 11:69–86CrossRefGoogle Scholar
  3. 3.
    Sijia W, Elisabeth Z, Keenan W et al (2013) Phage therapy: future inquiries. Postdoc J 1(6):24–35Google Scholar
  4. 4.
    Agata AC, Iwona D, Karolina PG et al (2017) Phage therapy in bacterial infections treatment: one hundred years after the discovery of Bacteriophages. Curr Microbiol 74:277–283CrossRefGoogle Scholar
  5. 5.
    Ry Y, Jason JG (2015) Phage therapy redux—what is to be done? Science 350(6265):1163–1164CrossRefGoogle Scholar
  6. 6.
    Susan Z, Andrzej G, Krystyna D (2017) Delivering phage therapy per os: benefits and barriers. Expert Rev Anti-Infe 15(2):167–179CrossRefGoogle Scholar
  7. 7.
    Hanlon GW (2007) Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int. J. Antimicrob Agents 30(2):118–128CrossRefPubMedGoogle Scholar
  8. 8.
    Marcelyn TM, Muchaneta GM, Hilda AM et al (2017) Carriage of antibiotic-resistant Enterobacteriaceae in hospitalised children in tertiary hospitals in Harare. Antimicrobial Resis Infect Control, Zimbabwe. CrossRefGoogle Scholar
  9. 9.
    Helen WB, George HT, John SB et al (2009) Bad bugs, no drugs: No ESKAPE! an update from the infectious diseases Society of America. Clin Infect Dis 48:1–12CrossRefGoogle Scholar
  10. 10.
    Stephen TA (2016) Commentary: phage therapy of Staphylococcal chronic osteomyelitis in experimental animal model. Front Microbiol. CrossRefGoogle Scholar
  11. 11.
    Raul RR, Rebecca AO, Ben MM et al (2011) Naturally resident and exogenously applied T4-like and T5-like bacteriophages can reduce Escherichia coli O157:H7 levels in sheep guts. Bacteriophage 1:15–24CrossRefGoogle Scholar
  12. 12.
    Kumarappan A, Valliappan K, Balaraman D (2016) Protective effect of phages on experimental V. parahaemolyticus infection and immune response in shrimp (Fabricius, 1798). Aquaculture 453:86–92CrossRefGoogle Scholar
  13. 13.
    Leron K, Mor S, Shaul B et al (2016) Phage therapy against Enterococcus faecalis in dental root canals. J Oral Microbiol 8:1–11Google Scholar
  14. 14.
    Mike B, Diana RA, Mark CE et al (2015) Assessing phage therapy against Pseudomonas aeruginosa using a Galleria mellonella infection model. Int J Antimicrob Agents 46:196–200CrossRefGoogle Scholar
  15. 15.
    Yanyan Z, Heather KH, Zhiqiang H (2013) Application of bacteriophages to selectively remove Pseudomonas aeruginosa in water and wastewater filtration systems. Water Res 47:4507–4518CrossRefGoogle Scholar
  16. 16.
    Jeongdong C, Shireen MK, Ramesh G (2010) Bacteriophage-based biocontrol of biological sludge bulking in wastewater. Bioeng Bugs 2:214–217Google Scholar
  17. 17.
    Adams MH (1959) Bacteriophages. Interscience Publishers, LondonGoogle Scholar
  18. 18.
    Green MR, Sambrook J (2012) Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press Cold Spring Harbor, New YorkGoogle Scholar
  19. 19.
    Arndt D, Grant JR, Marcu A et al (2016) PHASTER: a better, faster version of the PHAST phage search tool. Nucleic Acids Res. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Koichiro T, Daniel P, Nicholas P et al (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28(10):2731–2739CrossRefGoogle Scholar
  21. 21.
    Fenton Mark, Paul R, Olivia MA et al (2010) Recombinant bacteriophage lysins as antibacterials. Bioengineered Bugs 1:9–16CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Young R, Blasi U (1995) Holins: form and function in bacteriophage lysis. FEMS Microbiol Rev 17:191–205CrossRefPubMedGoogle Scholar
  23. 23.
    Yibo S, Ning L, Yaxian Y et al (2012) Combined antibacterial activity of phage lytic proteins holin and lysin from Streptococcus suis Bacteriophage SMP. Curr Microbiol 65(1):28–34CrossRefGoogle Scholar
  24. 24.
    Dwayne RR, David MD (2015) Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage 5(3):e1062590 (1–16) CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • Honghui Liu
    • 1
  • Yanwen Xiong
    • 2
  • Xinchun Liu
    • 1
    Email author
  • Jinqing Li
    • 1
  1. 1.Environmental Science, College of Resources and EnvironmentUniversity of Chinese Academy of SciencesBeijingChina
  2. 2.Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory of Infectious Disease Prevention and ControlNational Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and PreventionBeijingChina

Personalised recommendations